32
Participants
Start Date
September 30, 2010
Primary Completion Date
October 31, 2012
Study Completion Date
January 31, 2013
TAK-960
TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle. A 3 + 3 dose escalation scheme will be employed.
South Texas Accelerated Research Therapeutics (START), San Antonio
Huntsman Cancer Institute, Salt Lake City
Lead Sponsor
Millennium Pharmaceuticals, Inc.
INDUSTRY